GWM
PTCT icon

Gilpin Wealth Management’s PTC Therapeutics PTCT Stock Holding History

Gilpin Wealth Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$324 Sell
5
-6
-55% -$437 ﹤0.01% 981
2026
Q2 		$898 Sell
11
-3
-21% -$217 ﹤0.01% 524
2026
Q1 		$954 Buy
14
+8
+133% +$567 ﹤0.01% 487
2025
Q4 		$456 Buy
+6
New +$436 ﹤0.01% 463

Other funds holding PTCT

JWS
Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $1.15B AUM 43.46% 1-Year Est. Return
SA
Sacks & Associates Warren, New Jersey $143M AUM 17.48% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

Gilpin Wealth Management's PTCT Position: Q3 2026 in Review

Gilpin Wealth Management reduced its PTC Therapeutics (PTCT) stake by 55% in Q3 2026, selling an estimated $437 and leaving 5 shares worth $324. The position accounts for ﹤0.01% of the portfolio, ranked #981.

Gilpin Wealth Management first reported a position in PTCT in Q4 2025 and has held it in 4 quarters since. The position peaked at $954 in Q1 2026. 8 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.

  • Gilpin Wealth Management held 5 shares of PTC Therapeutics worth $324 as of Q3 2026.
  • Gilpin Wealth Management sold 6 PTC Therapeutics shares in Q3 2026, an estimated $437.
  • PTC Therapeutics made up ﹤0.01% of Gilpin Wealth Management's portfolio in Q3 2026, its #981 holding.
  • Gilpin Wealth Management first reported a position in PTC Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Gilpin Wealth Management's PTC Therapeutics position peaked at $954 in Q1 2026.
  • 8 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.

Based on Gilpin Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.